1. Ireland Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Medtronic plc

Medtronic plc

2M6.DE
Medtronic plcDE flagDeutsche Börse
66.42
EUR
+2.76
- -
85.28BMarket Cap
Medtronic plc
2M6.DE
(Deutsche Börse)

Recent

price

66.42

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
13.91
14.39
15.36
16.28
16.97
18.49
20.45
21.55
22.08
22.7
21.57
22.39
23.6
23.48
24.38
26.09
27.68
Revenue per Share
2.8
2.87
3.43
3.4
3.06
2.44
2.51
2.92
2.29
3.44
3.57
2.68
3.75
2.83
2.77
3.63
3.6
Basic EPS, GAAP
3.16
2.96
3.77
4.4
4.55
3.95
2.96
4.08
2.67
4.36
4.49
3.63
4.45
3.44
3.92
4.03
4.22
Free Cash Flow per Basic Share
0.82
0.9
0.97
1.04
1.11
1.22
1.52
1.72
1.84
2
2.16
2.32
2.52
2.72
2.76
2.79
2.83
Dividend per Share
13.5
15.03
16.69
18.8
20
49.67
15.4
16.88
17.97
19.51
20.98
21.26
22.53
22.85
22.9
24.48
25.19
Book Value per Share
3.33
3.46
4.3
5.56
6.55
-14.06
-11.59
-8.41
-7.7
-7.66
-5.99
-6.02
-2.51
-3.46
-2.86
-4
-2.36
Tangible Book Value per Share
1,106
1,077
1,054
1,019
1,002
1,096
1,410
1,379
1,357
1,346
1,341
1,345
1,342
1,330
1,328
1,286
1,282
Basic Weighted Avg Shares
15,392
15,508
16,184
16,590
17,005
20,261
28,833
29,710
29,953
30,557
28,913
30,117
31,686
31,227
32,364
33,537
35,483
Sales/Revenue/Turnover
31.1
28.76
27.7
28.75
28.33
22.49
20.67
20.15
20.14
21.7
18.06
16.25
18.65
18.67
17.06
19.5
18.63
Operating Margin (%)
772
804
833
819
850
1,306
2,820
2,917
2,644
2,659
2,663
2,702
2,707
2,697
2,647
2,861
3,082
Depreciation Expense
3,099
3,096
3,617
3,467
3,065
2,675
3,538
4,028
3,104
4,631
4,789
3,606
5,039
3,758
3,676
4,662
4,613
Net Income, GAAP
21.83
16.62
17.61
18.44
17.27
23.26
18.4
12.56
45.46
10.53
- -
6.8
8.27
29.46
23.42
16.63
16.59
Effective Tax Rate (%)
20.13
19.96
22.35
20.9
18.02
13.2
12.27
13.56
10.36
15.16
16.56
11.97
15.9
12.03
11.36
13.9
13
Profit Margin (%)
4,718
4,424
10,409
13,902
15,651
21,671
16,435
10,609
12,896
13,495
11,665
14,039
10,665
12,624
11,146
10,935
14,576
Working Capital
6,944
7,934
7,192
9,691
10,259
33,673
30,020
25,881
23,705
24,477
22,021
26,378
20,372
24,344
23,932
25,642
27,880
LT Debt
14,629
15,968
17,113
18,671
19,443
53,230
52,063
50,330
50,822
50,212
50,872
51,602
52,722
51,665
50,420
48,256
49,196
Total Equity
16.83
14.88
13.88
13.67
13.14
5.75
5.6
6.24
4.07
7.74
- -
5.92
6.97
5.34
5.51
7.06
7.12
Return on Invested Capital (%)
15.3
13.8
14.49
13.09
10.96
5.2
6.52
9.11
6.98
11.58
- -
8.21
10.07
7.64
7.59
9.05
8.73
Return on Capital (%)
21.89
19.89
21.42
18.87
15.64
7.19
9.3
17.91
13.03
18.29
17.61
12.71
17.13
12.39
12.09
15.07
14.5
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jul'26
Oct'26
Jan'26
ST Debt
2,430
1,420
191
LT Borrowings
26,128
27,625
27,822
LT Finance Leases
51
55
58
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,282
1,282
1,283
Market Capitalization
116,603
116,563
129,802

Working Capital

FRC

•

in mil. unless spec.
Jul'26
Oct'26
Jan'26
Total Current Assets
23,223
23,996
24,071
Cash, Cash Equivalents & STI
8,121
8,327
8,383
Accounts Receivable, Net
6,263
6,389
6,359
Inventories
5,886
6,156
6,309
Total Current Liabilities
11,530
9,935
9,495
Payables & Accruals
7,084
6,384
6,723
ST Debt
2,430
1,420
191
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.95%
-1.02%
-4.29%
Free Cash Flow
5.38%
-1.33%
-0.29%
Net Income, GAAP
9%
2.85%
26.82%
Sales/Revenue/Turnover
5.8%
3.04%
3.62%
Total Cash Common Dividend
11.39%
4.48%
-2.1%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,702
7,984
8,089
8,589
32,364
2025
7,915
8,403
8,292
8,927
33,537
2026
8,578
8,961
9,017
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.59
0.68
0.99
0.49
2.77
2025
0.81
0.99
1.01
0.82
3.63
2026
0.81
1.07
0.89
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.69
0.69
0.69
0.69
2.76
2025
0.69
0.7
0.7
0.7
2.79
2026
0.71
0.71
0.71
- -
- -
Similar Companies
Cell MedX Corp. (CMXC)
ZimVie Inc. (ZIMV)
Surmodics, Inc. (SRDX)
Globus Medical, Inc. (GMED)
Holdco Nuvo Group D.G Ltd. Warrants (NUVOW)
Theralase Technologies Inc. (TLT.V)
Business
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The company operates through four main segments: Cardiovascular Portfolio, including cardiac rhythm management devices, heart failure products, structural heart and aortic products, and coronary and peripheral vascular products; Neuroscience Portfolio, encompassing cranial and spinal technologies, neuromodulation therapies such as deep brain stimulation and spinal cord stimulation, and surgical technologies; Medical Surgical Portfolio, featuring advanced surgical technologies, endoscopy products, ear, nose, and throat devices, and pelvic health solutions; and Diabetes Operating Unit, offering insulin pumps, continuous glucose monitoring systems, smart insulin pens, and consumables. Founded in 1949 and headquartered in Dublin, Ireland, with operational headquarters in Minneapolis, Minnesota, Medtronic serves customers in more than 150 countries and employs over 95,000 people. Recent developments include the appointment of Thierry Piéton as Chief Financial Officer effective March 2025, the launch of BrainSense Adaptive Deep Brain Stimulation as the world's first closed-loop DBS system, a new rechargeable neurostimulator in the Percept family, board additions of John Groetelaars and Bill Jellison with formation of Growth and Operating committees, FDA approval and Medicare coverage for the Symplicity renal denervation procedure for hypertension, and plans to spin off its diabetes business as MiniMed.